Lab Launch has worked with over 40 life sciences startups since 2015. We select companies based on their team, making Lab Launch a collaborative, enjoyable place to develop top-notch biotechnology. It turns out that good community members are pretty great at starting companies. Many of our current and former members have raised significant funding and over 94% are still in business.
Current Resident Companies
Founded in 1976, StatLab Medical Products is a leading developer and manufacturer of cost- effective histology, cytology and immunohistochemistry diagnostic supplies. StatLab offers 1,750 of the most commonly purchased diagnostic supplies used by independent and hospital-based anatomic pathology laboratories. Over 3,000 anatomic pathology laboratories across the United States rely on StatLab to satisfy their diagnostic supply requirements.
Quantum Screening Inc. is a biotechnology company engaged in developing saliva-based point of care, non-invasive, low-cost screening and detection tests to create revolutionary improvements in human health. Quantum’s founder, Uttam Sinha, MS, MD, FACS, and his team have spent the last 15 years developing a point-of-care test for oral cancer that will allow physicians to give conclusive results to their patients in a matter of minutes.
Paradigm is developing novel disruptive IgG Fc fusion and immunoregulatory proteins for prophylactic and therapeutic use against SARS CoV-2 and other viral, autoimmune and cancer markets with large unmet medical needs.
Paradigm is working with a large pharma company to advance a novel variant agnostic prophylactic and therapeutic against SARS CoV-2 using the virus' receptor ACE2 as an ultra-high affinity decoy, thereby avoiding SARS CoV-2 escape mutations which have rendered traditional FDA EUA monoclonal antibodies useless against novel SARS CoV-2 variants and subvariants.
Our goal is to provide the necessary tools for doctors and medical staff to make optimal treatment decisions that can ultimately improve public health as a whole. We believe our technology and processes can replace or augment current diagnostic paradigms in a range of settings, such as hospitals, independent diagnostic testing facilities, veterinary and livestock clinics, and research institutions. PathoGene’s patented, fully-automated, sample-to-answer IVD medical device will detect and identify all infectious bacterial, viral, fungal, and parasitic pathogens and profile antimicrobial resistance in clinical samples.
Mission Trail BioLabs is a California life sciences start-up company that aims to support the infectious disease research community by providing superior recombinant proteins for laboratory use. Our protein products will be carefully tested for high purity, activity, and functionality ahead of shipping. Our vision is to place the best lab reagents in the hands of infectious disease scientists around the world at an affordable price.
Founded in 2017, XDemics Corporation is a National Institutes of Health-funded biotech company developing intensified bioreactors and complementing production processes to support affordable access to gene therapies, oncolytic medicines, and other biologic products. Our AAV superproduction process achieves unparalleled productivity of 1E16vg/L helping customers overcome bottlenecks and drive down costs. Nicole Bergman, JD, is President and CEO of XDemics Corporation. She has over 25 years of experience in corporate finance and project finance law, where she has helped companies, in particular medical device companies, move through the corporate life cycle from organization to financing to public finance to merger and sale.
We are a science company dedicated to providing entrepreneurs with the next generation of cannabis-based innovations. In collaboration with industry leading scientists and research partners from around the world, we develop the highest quality cannabis compounds for cultivators, extractors, agencies, brands & manufacturers at every point along the supply chain.